947403-75-0

Basic information

• Product Name: 4-AMino-5,6-dihydro-2H-pyridine-1,3-dicarboxylicacid1-tert-butylester3-ethylester
• Synonyms: 4-AMino-5,6-dihydro-2H-pyridine-1,3-dicarboxylicacid1-tert-butylester3-ethylester;1-tert-Butyl 3-ethyl 4-aMino-5,6-dihydropyridine-1,3(2H)-dicarboxylate
• CAS NO: 947403-75-0
• Molecular Formula: C₁₃H₂₂N₂O₄
• Molecular Weight: 270.32478
• Mol File: 947403-75-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-AMino-5,6-dihydro-2H-pyridine-1,3-dicarboxylicacid1-tert-butylester3-ethylester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMino-5,6-dihydro-2H-pyridine-1,3-dicarboxylicacid1-tert-butylester3-ethylester(947403-75-0)
• EPA Substance Registry System: 4-AMino-5,6-dihydro-2H-pyridine-1,3-dicarboxylicacid1-tert-butylester3-ethylester(947403-75-0)

Safety Data

• Hazardous Substances Data: 947403-75-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-Amino-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butylester 3-ethylester is used as a key intermediate in organic synthesis for the preparation of various chemical compounds. Its versatile structure allows for further functionalization and modification, making it a valuable building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-Amino-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butylester 3-ethylester is used as a starting material for the development of potential drug candidates. Its unique structure and functional groups make it a promising candidate for the design and synthesis of new therapeutic agents with novel mechanisms of action.
Used in Drug Discovery:
4-Amino-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butylester 3-ethylester is employed as a chemical probe in drug discovery efforts. Its ability to interact with various biological targets and modulate their activity makes it a valuable tool for identifying new therapeutic leads and understanding the underlying mechanisms of diseases.
Used in Medicinal Chemistry:
In medicinal chemistry, 4-Amino-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butylester 3-ethylester is utilized for the optimization of drug candidates. Its unique structural features and functional groups can be modified to improve the pharmacokinetic and pharmacodynamic properties of potential drugs, leading to the development of more effective and safer therapeutic agents.
Overall, 4-Amino-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butylester 3-ethylester is a versatile and valuable chemical compound with a wide range of applications in various scientific and industrial fields. Its unique structure and properties make it an essential component in the development of new chemical compounds, drug candidates, and therapeutic agents.

Upstream product

• 4644-61-5 ethyl 4-piperidone-3-carboxylate hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 98977-34-5 1-tert-butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate 

Downstream Products

• 1073722-88-9 C₂₇H₃₃N₃O₄S 
• 1073722-86-7 C₂₇H₃₃N₃O₅ 

Relevant articles and documents

Development of Novel Anticancer Agents with a Scaffold of Tetrahydropyrido[4,3- d]pyrimidine-2,4-dione

ONC201 is a small molecular anticancer agent currently in multiple Phase II clinical trials. Based on the pharmacophore of ONC201, a series of small molecular compounds with a core structure of tetrahydropyrido[4,3-d]pyrimidine-2,4-dione were designed and synthesized. Preliminary mechanism studies of these compounds indicated that they can inhibit the phosphorylation of AKT and ERK, induce the dephosphorylation of Foxo3a, and promote the expression of TRAIL and the enhancement of activating transcription factor 4 (ATF4) in PC-3 cells. Structure-activity relationship (SAR) studies indicated that modifications of the substituted groups on the core structure can significantly improve the cellular activities of these compounds. The most potent compounds are over 100 times more potent than ONC201 in inhibition of cell growth in a panel of different types of human cancer cell lines.

NOVEL TETRAHYDROPYRIDOPYRIMIDINONE DERIVATIVE

An object is to provide a novel compound having a higher MGAT2 inhibitory activity than conventional compounds. A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof is provided.

COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND

The present invention relates to a bicyclic pyrimidine compound of the following formula (I) or a salt thereof. wherein R1 is lower alkyl, cyclic lower alkyl. etc.; R2 is H, lower alkyl, lower alkenyl, etc.; R3 is H, lower alkyl, lower alkenyl, etc.; X is O, S or -N(R4)-; R4 is H or lower alkyl; or R2 and R4 may combine each other to form cyclic amino; Y is amido, keto, sulfonyl, etc.; R5 is H or lower alkyl; Z is O or S; m and n are 1 or 2. Said compound (I) or a salt thereof have MGAT inhibitory activity, and are useful as an agent for treatment or prophylaxis of adiposity, metabolic syndromes, hyperlipidemia, hyper neutral lipemia, hyper VLDL-mia, hyper fatty acidemia, diabetes mellitus, arteriosclerosis.

PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disease, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists

The present article describes a selection of a new class of small molecule antagonists for the h-GnRH receptor, their preparation, and evaluation in vitro. Three computational methods were combined into a consensus score, to rank order virtual templates. The top 5% of templates were further evaluated in silico and assessed for novelty and synthetic accessibility. The tetrahydropyrido[4,3-d]pyrimidine-2,4-dione core was selected for synthesis and evaluated in vitro. Using an array approach for analog design and synthesis, we were able to drive the binding below 10 nM for the h-GnRH receptor after two rounds of optimization.